(Albany, United States) As per DelveInsight’s assessment, globally, the Fallopian Tube Cancer pipeline constitutes 70+ key companies continuously working towards developing 70+ Fallopian Tube Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Fallopian Tube Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Fallopian Tube Cancer clinical trials studies, Fallopian Tube Cancer NDA approvals (if any), and product development activities comprising the technology, Fallopian Tube Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Fallopian Tube Cancer pipeline treatment landscape of the report, click here @ Fallopian Tube Cancer Pipeline Outlook

 

Key Takeaways from the Fallopian Tube Cancer Pipeline Report

• DelveInsight’s Fallopian Tube Cancer Pipeline analysis depicts a robust space with 70+ active players working to develop 70+ pipeline treatment therapies.
• The leading Fallopian Tube Cancer Companies working in the market include ImmunoGen, Janssen Research & Development, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee’s Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, and others
• Promising Fallopian Tube Cancer Pipeline Therapies in the various stages of development include hu3S193, Mirvetuximab soravtansine, Cetuximab, Carboplatin, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin, Bevacizumab, Carboplatin, and others
• On April 2023, ImmunoGen Inc announced a study of phase 2 clinical trials for Mirvetuximab soravtansine. PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
• On June 2023, Bristol-Myers Squibb announced a study of phase 2 clinical trials for MORAb-202, Paclitaxel, and Topotecan. The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator’s choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
• On June 2023, zr Pharma & GmbH announced a study of phase 3 clinical trials for Rucaparib. Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

 

Fallopian Tube Cancer Overview

Fallopian Tube Cancer starts in the fallopian tubes, which connect a woman’s ovaries to their uterus. Fallopian Tube Cancer is very rare. Only about 1% of all reproductive cancers in women start in the fallopian tubes.

 

To explore more information on the latest breakthroughs in the Fallopian Tube Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight

 

Fallopian Tube Cancer Emerging Drugs Profile

• Mirvetuximab Soravtansine: ImmunoGen
• Tisotumab vedotin: Genmab/Seagen
• Pembrolizumab: Merck & Co.

 

Fallopian Tube Cancer Pipeline Therapeutics Assessment

There are approx. 70+ key Fallopian Tube Cancer companies which are developing the Fallopian Tube Cancer therapies. The companies which have their Fallopian Tube Cancer drug candidates in the most advanced stage, i.e. Phase III include, Immunogen.

 

Request a sample and discover the recent advances in Fallopian Tube Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight

 

Fallopian Tube Cancer Drugs and Companies

• Mirvetuximab soravtansine: ImmunoGen Inc
• Paclitaxel: Bristol-Myers Squibb
• AMG 386: Amgen
• Gemcitabine: Genentech Inc

 

Fallopian Tube Cancer Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Fallopian Tube Cancer Therapeutics Market include-

ImmunoGen, Janssen Research & Development, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee’s Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, and others.

 

Dive deep into rich insights for drugs for Fallopian Tube Cancer Pipeline, click here for Fallopian Tube Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight

 

Scope of the Fallopian Tube Cancer Pipeline Report

• Coverage- Global
• Fallopian Tube Cancer Companies- ImmunoGen, Janssen Research & Development, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee’s Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, and others.
• Fallopian Tube Cancer Therapies- hu3S193, Mirvetuximab soravtansine, Cetuximab, Carboplatin, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin, Bevacizumab, Carboplatin, and others
• Fallopian Tube Cancer Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Fallopian Tube Cancer Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Fallopian Tube Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Fallopian Tube Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Fallopian Tube Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Mirvetuximab Soravtansine: ImmunoGen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Gimatecan: Lee’s Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. TG4050: Transgene
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Fallopian Tube Cancer Key Companies
20. Fallopian Tube Cancer Key Products
21. Fallopian Tube Cancer- Unmet Needs
22. Fallopian Tube Cancer- Market Drivers and Barriers
23. Fallopian Tube Cancer- Future Perspectives and Conclusion
24. Fallopian Tube Cancer Analyst Views
25. Fallopian Tube Cancer Key Companies
26. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services